Table 1.
Patient baseline characteristics by POD24 status
| Died | Progressed within 24 months | Alive and progression free | Total | |
|---|---|---|---|---|
| (n = 130) | (n = 1531) | (n = 3564) | (n = 5225) | |
| Age | ||||
| Mean (SD) | 60.4 (11.01) | 55.2 (11.14) | 55.0 (11.13) | 55.2 (11.16) |
| Median (range) | 62.0 (29.0-81.0) | 56.0 (17.0-84.0) | 56.0 (19.0-90.0) | 56.0 (17.0-90.0) |
| Sex, n (%) | ||||
| Female | 50 (38.5) | 697 (45.5) | 1811 (50.8) | 2558 (49.0) |
| Male | 80 (61.5) | 834 (54.5) | 1753 (49.2) | 2667 (51.0) |
| Performance status, n (%) | ||||
| 0-1 | 90 (76.3) | 1372 (91.5) | 3315 (95.5) | 4777 (93.9) |
| ≥2 | 28 (23.7) | 127 (8.5) | 158 (4.5) | 313 (6.1) |
| Data missing | 12 | 32 | 91 | 135 |
| Rituximab, n (%) | ||||
| No | 85 (68.5) | 896 (59.1) | 1450 (40.8) | 2431 (46.8) |
| Yes | 39 (31.5) | 619 (40.9) | 2106 (59.2) | 2764 (53.2) |
| Data missing | 6 | 16 | 8 | 30 |
| Anthracycline, n (%) | ||||
| No | 61 (49.2) | 689 (45.5) | 1196 (33.6) | 1946 (37.5) |
| Yes | 63 (50.8) | 826 (54.5) | 2360 (66.4) | 3249 (62.5) |
| Data missing | 6 | 16 | 8 | 30 |
| Treatment group, n (%) | ||||
| Chemotherapy | 87 (66.9) | 923 (60.3) | 1535 (43.1) | 2545 (48.7) |
| Rituximab+chemotherapy | 43 (33.1) | 486 (31.7) | 1881 (52.8) | 2410 (46.1) |
| Rituximab monotherapy | 0 (0.0) | 122 (8.0) | 148 (4.2) | 270 (5.2) |
| Months from diagnosis to treatment | ||||
| Mean (standard deviation) | 1.9 (4.76) | 3.6 (11.29) | 3.0 (8.26) | 3.1 (9.17) |
| Median (range) | 0.8 (0.0-36.5) | 0.9 (0.0-160.3) | 1.1 (0.0-142.2) | 1.0 (0.0-160.3) |
| Ann Arbor stage, n (%) | ||||
| Unknown | 2 (1.5) | 3 (0.2) | 17 (0.5) | 22 (0.4) |
| I/II | 7 (5.4) | 52 (3.4) | 242 (6.8) | 301 (5.8) |
| III/IV | 121 (93.1) | 1476 (96.4) | 3305 (92.7) | 4902 (93.8) |
| FLIPI risk category | ||||
| Low, n (%) | 12 (10.9) | 149 (10.3) | 694 (20.4) | 855 (17.2) |
| Intermediate, n (%) | 22 (20.0) | 457 (31.5) | 1344 (39.5) | 1823 (36.7) |
| High, n (%) | 76 (69.1) | 845 (58.2) | 1363 (40.1) | 2284 (46.0) |
| Data missing, n | 20 | 80 | 163 | 263 |
| Number of nodal sites | ||||
| 0-4, n (%) | 37 (44.6) | 306 (28.4) | 1084 (41.1) | 1427 (37.6) |
| >4, n (%) | 46 (55.4) | 772 (71.6) | 1553 (58.9) | 2371 (62.4) |
| Data missing, n | 47 | 453 | 927 | 1427 |
| HGB at baseline | ||||
| Normal, n (%) | 62 (59.6) | 839 (72.3) | 2471 (83.0) | 3372 (79.5) |
| Decreased, n (%) | 42 (40.4) | 322 (27.7) | 507 (17.0) | 871 (20.5) |
| Data missing, n | 26 | 370 | 586 | 982 |
| β2M level at baseline | ||||
| Normal, n (%) | 18 (37.5) | 520 (58.6) | 1667 (72.9) | 2205 (68.4) |
| Elevated, n (%) | 30 (62.5) | 368 (41.4) | 620 (27.1) | 1018 (31.6) |
| Data missing, n | 82 | 643 | 1277 | 2002 |